[Form 4] Quest Diagnostics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Patrick Plewman, Senior Vice President for Diagnostic Services at Quest Diagnostics Inc. (DGX), reported an insider sale under a Rule 10b5-1 plan. On 08/21/2025 he disposed of 1,975 shares of Quest Diagnostics common stock at $185 per share. Following the transaction, he beneficially owned 15,269 shares, held directly. The filing indicates the sale was executed pursuant to an established 10b5-1 trading plan and the Form 4 was signed by an attorney-in-fact on 08/25/2025. No derivative transactions or other securities were reported in this filing.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating a pre-established trading plan
• Clear disclosure of amounts: 1,975 shares sold at $185 and 15,269 shares retained
• Form signed and filed (attorney-in-fact signature dated 08/25/2025), demonstrating compliance with reporting rules

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine insider sale under a 10b5-1 plan; no governance red flags disclosed.

The filing shows a common-stock sale by a senior officer executed under a Rule 10b5-1 plan, which provides an affirmative defense to insider trading allegations when properly adopted. The report lists the exact share count sold (1,975) and remaining beneficial ownership (15,269), and it is signed by an attorney-in-fact, indicating administrative handling. There are no indications of material non-routine events, related-party transactions, or amendments that would suggest governance concerns in this disclosure.

Securities Analyst

TL;DR: Transaction is informational for holders but likely immaterial to company fundamentals.

The sale of 1,975 shares at $185 is a discrete insider liquidity event reported on Form 4. Because it was executed under a pre-established 10b5-1 plan and leaves the reporting person with 15,269 shares, this appears to be routine insider selling rather than a reaction to undisclosed company developments. The filing contains no new financial metrics or operational changes that would affect valuation models.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plewman Patrick

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP for Diagnostic Services

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		S(1)		1,975	D	$185	15,269	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Remarks:

	Sean D. Mersten, Attorney in Fact for Patrick Plewman	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Patrick Plewman report for DGX?

He reported the sale of 1,975 shares of Quest Diagnostics common stock on 08/21/2025 at $185 per share.

Was the sale by Patrick Plewman part of a 10b5-1 plan?

Yes, the Form 4 states the sale was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

How many Quest Diagnostics shares does Plewman own after the reported transaction?

Following the reported transaction, he beneficially owned 15,269 shares, held directly.

Who signed the Form 4 filing on behalf of Patrick Plewman?

The Form 4 shows it was signed by Sean D. Mersten, Attorney in Fact for Patrick Plewman on 08/25/2025.

Does this Form 4 disclose any options or derivative transactions for DGX?

No. Table II for derivative securities contains no reported transactions; only a common stock sale is listed in Table I.